S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   271.10 (+3.29%)
FB   168.83 (+1.98%)
MSFT   169.60 (+2.62%)
AMZN   2,011.60 (+0.70%)
CGC   14.48 (+0.98%)
NVDA   259.03 (-3.49%)
BABA   199.99 (+1.80%)
MU   46.54 (+0.37%)
GE   7.02 (-2.90%)
TSLA   545.45 (+5.66%)
AMD   49.02 (+3.16%)
T   30.38 (+3.19%)
ACB   0.81 (+1.25%)
F   4.71 (+3.97%)
NFLX   372.28 (+0.05%)
BAC   22.82 (+6.69%)
GILD   74.67 (-3.94%)
DIS   104.95 (+5.39%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   271.10 (+3.29%)
FB   168.83 (+1.98%)
MSFT   169.60 (+2.62%)
AMZN   2,011.60 (+0.70%)
CGC   14.48 (+0.98%)
NVDA   259.03 (-3.49%)
BABA   199.99 (+1.80%)
MU   46.54 (+0.37%)
GE   7.02 (-2.90%)
TSLA   545.45 (+5.66%)
AMD   49.02 (+3.16%)
T   30.38 (+3.19%)
ACB   0.81 (+1.25%)
F   4.71 (+3.97%)
NFLX   372.28 (+0.05%)
BAC   22.82 (+6.69%)
GILD   74.67 (-3.94%)
DIS   104.95 (+5.39%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   271.10 (+3.29%)
FB   168.83 (+1.98%)
MSFT   169.60 (+2.62%)
AMZN   2,011.60 (+0.70%)
CGC   14.48 (+0.98%)
NVDA   259.03 (-3.49%)
BABA   199.99 (+1.80%)
MU   46.54 (+0.37%)
GE   7.02 (-2.90%)
TSLA   545.45 (+5.66%)
AMD   49.02 (+3.16%)
T   30.38 (+3.19%)
ACB   0.81 (+1.25%)
F   4.71 (+3.97%)
NFLX   372.28 (+0.05%)
BAC   22.82 (+6.69%)
GILD   74.67 (-3.94%)
DIS   104.95 (+5.39%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   271.10 (+3.29%)
FB   168.83 (+1.98%)
MSFT   169.60 (+2.62%)
AMZN   2,011.60 (+0.70%)
CGC   14.48 (+0.98%)
NVDA   259.03 (-3.49%)
BABA   199.99 (+1.80%)
MU   46.54 (+0.37%)
GE   7.02 (-2.90%)
TSLA   545.45 (+5.66%)
AMD   49.02 (+3.16%)
T   30.38 (+3.19%)
ACB   0.81 (+1.25%)
F   4.71 (+3.97%)
NFLX   372.28 (+0.05%)
BAC   22.82 (+6.69%)
GILD   74.67 (-3.94%)
DIS   104.95 (+5.39%)
Log in

NASDAQ:EYENEyenovia Stock Price, Forecast & News

$2.82
+0.01 (+0.36 %)
(As of 04/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.89
Now: $2.82
$3.03
50-Day Range
$1.77
MA: $3.18
$4.44
52-Week Range
$1.11
Now: $2.82
$6.98
Volume2,190 shs
Average Volume80,127 shs
Market Capitalization$55.78 million
P/E RatioN/A
Dividend YieldN/A
Beta1.89
Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.
Read More
Eyenovia logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.93 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYEN
CUSIPN/A
Phone917-289-1117

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.71 per share

Profitability

Net Income$-21,160,000.00

Miscellaneous

EmployeesN/A
Market Cap$55.78 million
Next Earnings Date5/12/2020 (Estimated)
OptionableNot Optionable

Receive EYEN News and Ratings via Email

Sign-up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter.


Eyenovia (NASDAQ:EYEN) Frequently Asked Questions

How has Eyenovia's stock been impacted by COVID-19 (Coronavirus)?

Eyenovia's stock was trading at $2.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EYEN stock has decreased by 2.8% and is now trading at $2.82. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Eyenovia?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eyenovia.

When is Eyenovia's next earnings date?

Eyenovia is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Eyenovia.

How were Eyenovia's earnings last quarter?

Eyenovia Inc (NASDAQ:EYEN) issued its quarterly earnings data on Wednesday, March, 25th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.02. View Eyenovia's earnings history.

What price target have analysts set for EYEN?

3 Wall Street analysts have issued 12 month price targets for Eyenovia's shares. Their forecasts range from $6.00 to $9.00. On average, they expect Eyenovia's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 166.0% from the stock's current price. View analysts' price targets for Eyenovia.

Has Eyenovia been receiving favorable news coverage?

Media coverage about EYEN stock has trended very negative on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eyenovia earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutEyenovia.

Are investors shorting Eyenovia?

Eyenovia saw a decrease in short interest in February. As of February 28th, there was short interest totaling 233,900 shares, a decrease of 17.2% from the February 13th total of 282,400 shares. Based on an average trading volume of 65,400 shares, the days-to-cover ratio is currently 3.6 days. Approximately 2.4% of the shares of the company are short sold. View Eyenovia's Current Options Chain.

Who are some of Eyenovia's key competitors?

What other stocks do shareholders of Eyenovia own?

Who are Eyenovia's key executives?

Eyenovia's management team includes the following people:
  • Dr. Tsontcho Ianchulev M.P.H., M.D., MPH, CEO, Chief Medical Officer & Director (Age 46)
  • Ms. Jennifer Clasby, VP of Clinical Operations (Age 65)
  • Mr. Luke Clauson, VP of R&D (Age 40)
  • Mr. John P. Gandolfo, CFO & Sec. (Age 58)
  • Mr. Michael M. Rowe, VP of Marketing

When did Eyenovia IPO?

(EYEN) raised $30 million in an initial public offering (IPO) on Thursday, January 25th 2018. The company issued 2,700,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ served as the underwriters for the IPO.

What is Eyenovia's stock symbol?

Eyenovia trades on the NASDAQ under the ticker symbol "EYEN."

How do I buy shares of Eyenovia?

Shares of EYEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eyenovia's stock price today?

One share of EYEN stock can currently be purchased for approximately $2.82.

How big of a company is Eyenovia?

Eyenovia has a market capitalization of $55.78 million. The company earns $-21,160,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis.  View additional information about Eyenovia.

What is Eyenovia's official website?

The official website for Eyenovia is http://www.eyenoviabio.com/.

How can I contact Eyenovia?

Eyenovia's mailing address is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. The company can be reached via phone at 917-289-1117 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Featured Article: What is Call Option Volume?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel